- Home
- IGMS vs HTD Comparison
IGMS vs HTD Comparison
Compare IGMS & HTD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- HTD
- Stock Information
- Founded
- IGMS 1993
- HTD 2004
- Country
- IGMS United States
- HTD United States
- Employees
- IGMS N/A
- HTD N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- HTD Finance Companies
- Sector
- IGMS Health Care
- HTD Finance
- Exchange
- IGMS Nasdaq
- HTD Nasdaq
- Market Cap
- IGMS 962.1M
- HTD 796.0M
- IPO Year
- IGMS 2019
- HTD N/A
- Fundamental
- Price
- IGMS $9.47
- HTD $22.80
- Analyst Decision
- IGMS Hold
- HTD
- Analyst Count
- IGMS 8
- HTD 0
- Target Price
- IGMS $14.63
- HTD N/A
- AVG Volume (30 Days)
- IGMS 238.9K
- HTD 92.3K
- Earning Date
- IGMS 11-08-2024
- HTD 01-01-0001
- Dividend Yield
- IGMS N/A
- HTD 8.59%
- EPS Growth
- IGMS N/A
- HTD N/A
- EPS
- IGMS N/A
- HTD N/A
- Revenue
- IGMS $2,918,000.00
- HTD N/A
- Revenue This Year
- IGMS $298.54
- HTD N/A
- Revenue Next Year
- IGMS N/A
- HTD N/A
- P/E Ratio
- IGMS N/A
- HTD N/A
- Revenue Growth
- IGMS 57.64
- HTD N/A
- 52 Week Low
- IGMS $4.72
- HTD $16.17
- 52 Week High
- IGMS $22.50
- HTD $22.13
- Technical
- Relative Strength Index (RSI)
- IGMS 28.30
- HTD 46.93
- Support Level
- IGMS $10.91
- HTD $22.53
- Resistance Level
- IGMS $16.32
- HTD $23.25
- Average True Range (ATR)
- IGMS 1.53
- HTD 0.36
- MACD
- IGMS -0.79
- HTD -0.05
- Stochastic Oscillator
- IGMS 0.80
- HTD 52.80
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About HTD John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest
John Hancock Tax-advantaged Div Inc Fd is a closed-end, diversified management investment company. Its investment objective is to provide a high after-tax total return from dividend income and capital appreciation. The fund's portfolio composition consists of common stocks, preferred securities, corporate bonds, and short-term investments. Its sector composition comprises utilities, financials, energy, telecommunication services, industrials, healthcare, real estate, consumer discretionary and short-term investments.